cervical radiculopathy
Conditions
Interventions
Exercise, neuralmobilisation, wearing a neck collar
Sponsors
VU University Amsterdam
Eligibility
Inclusion criteria
Inclusion criteria: Cervical radiculopathy Inclusion • Age between 30-65 years. • Minimal score of 4 on the Numeric Pain Rating Scale (0-10). • Cervical radiculopathy based on the clinical diagnosis confirmed by the Magnetic Resonance Imaging (MRI through a medical specialist). The compression must be caused by a discus protrusion or herniation. • Written informed consent of the subject. • Referral by a medical specialist • High and mixed affinity binders for second generation TSPO radiotracers Healthy control group Inclusion • Age between 30-65 years. • Asymptomatic for neck or shoulder pain and other musculoskeletal conditions in the past 3 months. • Written informed consent of the subject. Referral by a medical specialist • High and mixed affinity binders for second generation TSPO radiotracers
Exclusion criteria
Exclusion criteria: Cervical radiculopathy and healthy control group A potential subject who meets any of the following criteria will be excluded from participation in this study: • Pregnancy or postpartum for 9 months • Contra-indications for venipuncture (e.g. phlebitis) • Underwent treatment for current complaints for the last 2 weeks (e.g. physiotherapy, manual therapy, general practitioner etc.) • Taken one of the following medications for the last 6 weeks: corticosteroids (e.g. prednisone), immunomodulatory medication (e.g. methotrexate, infliximab etc.) and the use of botox for the last 3 months. • Taken one of the following medication: NSAID’s (e.g. diclofenac, ibuprofen, naproxen etc.), Aspirin, Simvastatin (29) for the last week. • Benzodiazepine (30) use for the last six weeks. • MRI contraindications, (e.g. claustrophobia, inability to lie still in the scanner or metal objects in or around the body) • Inability to undergo PET-CT with administration of radioligand [¹¹C]-R-DP713. • Significant radiation exposure such that inclusion in this study will take the total dose >10mSv within the preceding 12 months. • Current participation in another clinical trial. • Previous participation in a PET-CT study in the last 12 months. • Having a medical disease with immune system involvement (e.g. MS, Spondylitis Ankylpoetica)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| [11C]-R-DPA713 SUV | — |
Secondary
| Measure | Time frame |
|---|---|
| delta[11C]-R-DPA713 SUV, ICC2.1, SDC | — |
Contacts
Public ContactIvo Lutke Schipholt
VU Amsterdam
Outcome results
None listed